Risk Factors and Anticoagulation Therapy in Patients With Isolated Distal Deep Vein Thrombosis in the Early

Yuping Li1, Junrong Ding1, Lei Shen1

  • 1Department of General Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Insights

Age and postoperative D-dimer levels predict isolated distal deep vein thrombosis (IDDVT) after thoracic surgery. Half-dose anticoagulation is effective and safe for IDDVT treatment, reducing medication needs post-discharge.

Area of Science:

  • Vascular Surgery
  • Thrombosis Research
  • Diagnostic Imaging

Background:

  • Isolated distal deep vein thrombosis (IDDVT) comprises about 50% of deep venous thrombosis (DVT) cases.
  • Current diagnostic and management strategies for IDDVT are not well-defined and remain controversial.
  • Thoracic surgery patients are a key population for DVT risk assessment.

Purpose of the Study:

  • To identify risk factors and predictors of IDDVT in patients undergoing thoracic surgery.
  • To evaluate the efficacy and safety of different anticoagulation therapy strategies for IDDVT.
  • To compare outcomes between full-dose and half-dose anticoagulation regimens.

Main Methods:

  • A cohort of 310 patients undergoing thoracic surgery were assessed using whole-leg ultrasonography and D-dimer level measurements.
  • Clinical data, including pre- and postoperative D-dimer levels and anticoagulant therapy, were collected.
  • Logistic regression analysis was employed to determine independent predictors of postoperative IDDVT.

Main Results:

  • Patients with IDDVT showed significantly higher age and postoperative D-dimer levels compared to the non-DVT group.
  • Postoperative D-dimer level emerged as a significant independent predictor of IDDVT, even after adjusting for age and surgical method.
  • Both full-dose and half-dose anticoagulation regimens demonstrated comparable safety profiles, with no significant adverse effects.
  • Half-dose therapy was associated with a significant reduction in the need for post-discharge anticoagulation medication.

Conclusions:

  • Elevated age and postoperative D-dimer levels are significant predictors of IDDVT following thoracic surgery.
  • Half-dose therapeutic anticoagulation is as effective as full-dose in preventing IDDVT progression.
  • Half-dose anticoagulation presents a safe and potentially more cost-effective treatment option for IDDVT patients post-thoracic surgery.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
88
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
101
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
66
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
105
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
88
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K